$ORIB
Orion Bliss Corp.

2023 Q2 Form 10-K Financial Statement

#000168316823004416 Filed on June 26, 2023

View on sec.gov

Income Statement

Concept 2023 Q2 2023 2022
Revenue $600.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin
YoY Change
% of Gross Profit
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses $29.78K $26.69K
YoY Change 11.58%
Operating Profit -$29.18K
YoY Change
Interest Expense
YoY Change
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income -$26.69K
YoY Change
Income Tax $0.00 $0.00
% Of Pretax Income
Net Earnings -$8.954K -$29.18K -$26.69K
YoY Change 9.34%
Net Earnings / Revenue -4863.67%
Basic Earnings Per Share $0.00 $0.00
Diluted Earnings Per Share $0.00 $0.00
COMMON SHARES
Basic Shares Outstanding 3.038M shares 3.038M shares 2.000M shares
Diluted Shares Outstanding 3.038M shares 2.000M shares

Balance Sheet

Concept 2023 Q2 2023 2022
SHORT-TERM ASSETS
Cash & Short-Term Investments
YoY Change
Cash & Equivalents $7.781K
Short-Term Investments
Other Short-Term Assets
YoY Change
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $7.915K
YoY Change 5806.72%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets
YoY Change
TOTAL ASSETS
Total Short-Term Assets $7.915K
Total Long-Term Assets
Total Assets
YoY Change
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable
YoY Change
Accrued Expenses
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $44.75K
YoY Change 56.76%
LONG-TERM LIABILITIES
Long-Term Debt
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $44.75K
Total Long-Term Liabilities
Total Liabilities
YoY Change
SHAREHOLDERS EQUITY
Retained Earnings -$57.80K
YoY Change 101.98%
Common Stock $304.00
YoY Change 52.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$36.84K
YoY Change
Total Liabilities & Shareholders Equity $7.915K
YoY Change 5806.72%

Cashflow Statement

Concept 2023 Q2 2023 2022
OPERATING ACTIVITIES
Net Income -$8.954K -$29.18K -$26.69K
YoY Change 9.34%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities -$29.18K -$26.82K
YoY Change 8.79%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities $36.96K $26.82K
YoY Change 37.8%
NET CHANGE
Cash From Operating Activities -$29.18K -$26.82K
Cash From Investing Activities
Cash From Financing Activities $36.96K $26.82K
Net Change In Cash $7.781K $0.00
YoY Change
FREE CASH FLOW
Cash From Operating Activities -$29.18K -$26.82K
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023 dei Entity Central Index Key
EntityCentralIndexKey
0001854183
CY2023 dei Amendment Flag
AmendmentFlag
false
CY2023 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
CY2023 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2022 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
usd
CY2023 dei Document Type
DocumentType
10-K
CY2023 dei Document Annual Report
DocumentAnnualReport
true
CY2023 dei Document Period End Date
DocumentPeriodEndDate
2023-04-30
CY2023 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--04-30
CY2023 dei Document Transition Report
DocumentTransitionReport
false
CY2023 dei Entity File Number
EntityFileNumber
333-257326
CY2023 dei Entity Registrant Name
EntityRegistrantName
ORION BLISS CORP.
CY2023 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
NV
CY2023 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
98-1591444
CY2023 dei Entity Address City Or Town
EntityAddressCityOrTown
Ashdod
CY2023 dei Entity Address Address Line1
EntityAddressAddressLine1
Kalonite 9-57
CY2023 dei Entity Address Country
EntityAddressCountry
IL
CY2023 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
7724233
CY2023 dei City Area Code
CityAreaCode
849
CY2023 dei Local Phone Number
LocalPhoneNumber
8593819
CY2023 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2023 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2023 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2023 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2023 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2023 dei Entity Small Business
EntitySmallBusiness
true
CY2023 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
CY2023 dei Entity Ex Transition Period
EntityExTransitionPeriod
true
CY2023 dei Document Fin Stmt Error Correction Flag
DocumentFinStmtErrorCorrectionFlag
false
CY2023 dei Entity Shell Company
EntityShellCompany
true
CY2022Q4 dei Entity Public Float
EntityPublicFloat
0 usd
CY2023Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
3038000 shares
CY2023 dei Auditor Firm
AuditorFirmId
5041
CY2023 dei Auditor Name
AuditorName
BF Borgers CPA PC
CY2023 dei Auditor Location
AuditorLocation
Lakewood, CO
CY2023Q2 us-gaap Escrow Deposit
EscrowDeposit
7781 usd
CY2022Q2 us-gaap Escrow Deposit
EscrowDeposit
0 usd
CY2023Q2 NONE Website Development Net
WebsiteDevelopmentNet
134 usd
CY2022Q2 NONE Website Development Net
WebsiteDevelopmentNet
134 usd
CY2023Q2 us-gaap Assets Current
AssetsCurrent
7915 usd
CY2022Q2 us-gaap Assets Current
AssetsCurrent
134 usd
CY2023Q2 NONE Accounts Payable Related Parties Current1
AccountsPayableRelatedPartiesCurrent1
25000 usd
CY2022Q2 NONE Accounts Payable Related Parties Current1
AccountsPayableRelatedPartiesCurrent1
13000 usd
CY2023Q2 NONE Due To Other Related Parties Classified Current1
DueToOtherRelatedPartiesClassifiedCurrent1
19752 usd
CY2022Q2 NONE Due To Other Related Parties Classified Current1
DueToOtherRelatedPartiesClassifiedCurrent1
15549 usd
CY2023Q2 us-gaap Liabilities Current
LiabilitiesCurrent
44752 usd
CY2022Q2 us-gaap Liabilities Current
LiabilitiesCurrent
28549 usd
CY2023Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2022Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
75000000 shares
CY2022Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
75000000 shares
CY2023Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
3038000 shares
CY2023Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
3038000 shares
CY2022Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
2000000 shares
CY2022Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
2000000 shares
CY2023Q2 us-gaap Common Stock Value
CommonStockValue
304 usd
CY2022Q2 us-gaap Common Stock Value
CommonStockValue
200 usd
CY2023Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
20656 usd
CY2022Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
0 usd
CY2023Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-57797 usd
CY2022Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-28615 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
-36837 usd
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
-28415 usd
CY2023Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
7915 usd
CY2022Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
134 usd
CY2023 us-gaap Revenues
Revenues
600 usd
CY2022 us-gaap Revenues
Revenues
0 usd
CY2023 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
29782 usd
CY2022 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
26690 usd
CY2023 us-gaap Operating Expenses
OperatingExpenses
29782 usd
CY2022 us-gaap Operating Expenses
OperatingExpenses
26690 usd
CY2023 us-gaap Profit Loss
ProfitLoss
-29182 usd
CY2022 us-gaap Profit Loss
ProfitLoss
-26690 usd
CY2023 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
CY2022 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
CY2023 us-gaap Net Income Loss
NetIncomeLoss
-29182 usd
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-26690 usd
CY2023 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.00
CY2023 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.00
CY2022 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.00
CY2022 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.00
CY2023 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
3038000 shares
CY2023 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
3038000 shares
CY2022 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
2000000 shares
CY2022 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
2000000 shares
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
0 usd
CY2021Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
200 usd
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-1925 usd
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
-1725 usd
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-26690 usd
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
-28415 usd
CY2023 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
20760 usd
CY2023 us-gaap Net Income Loss
NetIncomeLoss
-29182 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
-36837 usd
CY2023 us-gaap Net Income Loss
NetIncomeLoss
-29182 usd
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-26690 usd
CY2023 NONE Payments To Develop Website
PaymentsToDevelopWebsite
0 usd
CY2022 NONE Payments To Develop Website
PaymentsToDevelopWebsite
-134 usd
CY2023 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-29182 usd
CY2022 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-26824 usd
CY2023 us-gaap Proceeds From Repayments Of Related Party Debt
ProceedsFromRepaymentsOfRelatedPartyDebt
12000 usd
CY2022 us-gaap Proceeds From Repayments Of Related Party Debt
ProceedsFromRepaymentsOfRelatedPartyDebt
12000 usd
CY2023 us-gaap Proceeds From Related Party Debt
ProceedsFromRelatedPartyDebt
4203 usd
CY2022 us-gaap Proceeds From Related Party Debt
ProceedsFromRelatedPartyDebt
14824 usd
CY2023 us-gaap Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
20760 usd
CY2022 us-gaap Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
0 usd
CY2023 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
36963 usd
CY2022 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
26824 usd
CY2023 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
7781 usd
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
0 usd
CY2021Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
0 usd
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
7781 usd
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
0 usd
CY2023 us-gaap Interest Paid Net
InterestPaidNet
0 usd
CY2022 us-gaap Interest Paid Net
InterestPaidNet
0 usd
CY2023 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
0 usd
CY2022 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
0 usd
CY2023Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-57797 usd
CY2022Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-28615 usd
CY2023 us-gaap Use Of Estimates
UseOfEstimates
<p id="xdx_848_eus-gaap--UseOfEstimates_zqhczFjfRDx4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i><span id="xdx_86F_z1RUXtTSVrj5">Use of Estimates</span></i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i> </i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date the financial statements and the reported amount of revenues and expenses during the reporting period. Actual results could differ from those estimates.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p>
CY2023 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
0 shares
CY2023Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
75000000 shares
CY2023Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
3038000 shares
CY2023Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
3038000 shares
CY2023 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-6126 usd
CY2023 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
6126 usd
CY2023 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
CY2023Q2 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
12137 usd
CY2023Q2 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
12137 usd
CY2023Q2 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
0 usd
CY2023Q2 us-gaap Operating Loss Carryforwards
OperatingLossCarryforwards
57797 usd

Files In Submission

Name View Source Status
0001683168-23-004416-index-headers.html Edgar Link pending
0001683168-23-004416-index.html Edgar Link pending
0001683168-23-004416.txt Edgar Link pending
0001683168-23-004416-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
none-20230430.xsd Edgar Link pending
orionbliss_i10k-043023.htm Edgar Link pending
orion_ex3101.htm Edgar Link pending
orion_ex3201.htm Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R3.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
none-20230430_def.xml Edgar Link unprocessable
none-20230430_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
none-20230430_cal.xml Edgar Link unprocessable
none-20230430_lab.xml Edgar Link unprocessable
orionbliss_i10k-043023_htm.xml Edgar Link completed